Ocean Biomedical, Inc. financial data

Symbol
OCEA, OCEAW on Nasdaq
Industry
Pharmaceutical Preparations
Location
515 Madison Ave Suite 8078, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
Ocean Biomedical, Inc./DE (to 2/15/2023), Aesther Healthcare Acquisition Corp. (to 2/14/2023)
Latest financial report
10-K - Q4 2024 - Apr 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 3.9 % -20.6%
Debt-to-equity -102 % +1.26%
Return On Equity 10.5 % -93.5%
Return On Assets -555 % +89.1%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 166M shares +379%
Common Stock, Shares, Outstanding 34.9M shares +0.63%
Entity Public Float 5.47M USD +547391452%
Weighted Average Number of Shares Outstanding, Basic 27.5M shares +4.6%
Weighted Average Number of Shares Outstanding, Diluted 27.5M shares +4.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 342K USD -93.9%
General and Administrative Expense 3.77M USD -60.3%
Operating Income (Loss) -3.8M USD +62.8%
Nonoperating Income (Expense) -5.68M USD +94.6%
Net Income (Loss) Attributable to Parent -9.48M USD +91.7%
Earnings Per Share, Basic -0.34 USD/shares +92.2%
Earnings Per Share, Diluted -0.34 USD/shares +92.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 812K USD -61.5%
Assets 902K USD -83.6%
Accounts Payable, Current 15.9M USD -1.77%
Accrued Liabilities, Current 946K USD +113%
Liabilities, Current 33.9M USD +12.9%
Liabilities 98.5M USD +2.34%
Retained Earnings (Accumulated Deficit) -206M USD -4.84%
Stockholders' Equity Attributable to Parent -97.6M USD -7.55%
Liabilities and Equity 902K USD -83.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -485K USD +81.7%
Net Cash Provided by (Used in) Financing Activities 2.92M USD +388%
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 34.9M shares +0.63%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -485K USD -278%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 200K USD -80%
Deferred Tax Assets, Valuation Allowance 22.6M USD +8.83%
Deferred Tax Assets, Gross 22.6M USD +8.83%
Deferred Tax Assets, Operating Loss Carryforwards 7.64M USD +28.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares +700%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 108M USD +2.5%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 745K USD -38.2%
Interest Expense 50K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%